1
|
Rostamighadi M, Kamelshahroudi A, Mehta V, Zeng FY, Pass I, Chung TDY, Salavati R. High-throughput screening of compounds targeting RNA editing in Trypanosoma brucei: Novel molecular scaffolds with broad trypanocidal effects. Biochem Pharmacol 2024; 219:115937. [PMID: 37995979 DOI: 10.1016/j.bcp.2023.115937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 11/15/2023] [Accepted: 11/16/2023] [Indexed: 11/25/2023]
Abstract
Mitochondrial uridine insertion/deletion RNA editing, catalyzed by a multiprotein complex (editosome), is essential for gene expression in trypanosomes and Leishmania parasites. As this process is absent in the human host, a drug targeting this mechanism promises high selectivity and reduced toxicity. Here, we successfully miniaturized our FRET-based full-round RNA editing assay, which replicates the complete RNA editing process, adapting it into a 1536-well format. Leveraging this assay, we screened over 100,000 compounds against purified editosomes derived from Trypanosoma brucei, identifying seven confirmed primary hits. We sourced and evaluated various analogs to enhance the inhibitory and parasiticidal effects of these primary hits. In combination with secondary assays, our compounds marked inhibition of essential catalytic activities, including the RNA editing ligase and interactions of editosome proteins. Although the primary hits did not exhibit any growth inhibitory effect on parasites, we describe eight analog compounds capable of effectively killing T. brucei and/or Leishmania donovani parasites within a low micromolar concentration. Whether parasite killing is - at least in part - due to inhibition of RNA editing in vivo remains to be assessed. Our findings introduce novel molecular scaffolds with the potential for broad antitrypanosomal effects.
Collapse
Affiliation(s)
- Mojtaba Rostamighadi
- Institute of Parasitology, McGill University, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada
| | - Arezou Kamelshahroudi
- Institute of Parasitology, McGill University, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada
| | - Vaibhav Mehta
- Institute of Parasitology, McGill University, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada; Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada
| | - Fu-Yue Zeng
- Sanford Burnham Prebys Medical Discovery Institute, Conrad Prebys Center for Chemical Genomics, La Jolla, CA, USA
| | - Ian Pass
- Sanford Burnham Prebys Medical Discovery Institute, Conrad Prebys Center for Chemical Genomics, La Jolla, CA, USA
| | - Thomas D Y Chung
- Sanford Burnham Prebys Medical Discovery Institute, Conrad Prebys Center for Chemical Genomics, La Jolla, CA, USA
| | - Reza Salavati
- Institute of Parasitology, McGill University, Ste. Anne de Bellevue, Quebec H9X 3V9, Canada; Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada.
| |
Collapse
|
2
|
Stanford SM, Diaz MA, Ardecky RJ, Zou J, Roosild T, Holmes ZJ, Nguyen TP, Hedrick MP, Rodiles S, Guan A, Grotegut S, Santelli E, Chung TDY, Jackson MR, Bottini N, Pinkerton AB. Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase. J Med Chem 2021; 64:5645-5653. [PMID: 33914534 DOI: 10.1021/acs.jmedchem.0c02126] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Obesity-associated insulin resistance plays a central role in the pathogenesis of type 2 diabetes. A promising approach to decrease insulin resistance in obesity is to inhibit the protein tyrosine phosphatases that negatively regulate insulin receptor signaling. The low-molecular-weight protein tyrosine phosphatase (LMPTP) acts as a critical promoter of insulin resistance in obesity by inhibiting phosphorylation of the liver insulin receptor activation motif. Here, we report development of a novel purine-based chemical series of LMPTP inhibitors. These compounds inhibit LMPTP with an uncompetitive mechanism and are highly selective for LMPTP over other protein tyrosine phosphatases. We also report the generation of a highly orally bioavailable purine-based analogue that reverses obesity-induced diabetes in mice.
Collapse
Affiliation(s)
- Stephanie M Stanford
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Michael A Diaz
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Robert J Ardecky
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Jiwen Zou
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Tarmo Roosild
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Zachary J Holmes
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Tiffany P Nguyen
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Michael P Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Socorro Rodiles
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - April Guan
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Stefan Grotegut
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Eugenio Santelli
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Michael R Jackson
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Nunzio Bottini
- Department of Medicine, University of California, San Diego, La Jolla, California 92037, United States
| | - Anthony B Pinkerton
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| |
Collapse
|
3
|
Aboulnasr F, Krogman A, Graham RP, Cummins NW, Misra A, Garcia-Rivera E, Anderson JR, Natesampillai S, Kogan N, Aravamudan M, Nie Z, Chung TDY, Buick R, Feldman AL, King RL, Novak AJ, Ansell SM, Kenderian S, Badley AD. Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clin Cancer Res 2020; 26:5759-5771. [PMID: 32669373 PMCID: PMC7642027 DOI: 10.1158/1078-0432.ccr-20-0251] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 05/29/2020] [Accepted: 07/13/2020] [Indexed: 12/31/2022]
Abstract
PURPOSE TNF-related apoptosis inducing ligand (TRAIL) expression by immune cells contributes to antitumor immunity. A naturally occurring splice variant of TRAIL, called TRAILshort, antagonizes TRAIL-dependent cell killing. It is unknown whether tumor cells express TRAILshort and if it impacts antitumor immunity. EXPERIMENTAL DESIGN We used an unbiased informatics approach to identify TRAILshort expression in primary human cancers, and validated those results with IHC and ISH. TRAILshort-specific mAbs were used to determine the effect of TRAILshort on tumor cell sensitivity to TRAIL, and to immune effector cell dependent killing of autologous primary tumors. RESULTS As many as 40% of primary human tumors express TRAILshort by both RNA sequencing and IHC analysis. By ISH, TRAILshort expression is present in tumor cells and not bystander cells. TRAILshort inhibition enhances cancer cell lines sensitivity to TRAIL-dependent killing both in vitro and in immunodeficient xenograft mouse models. Immune effector cells isolated from patients with B-cell malignancies killed more autologous tumor cells in the presence compared with the absence of TRAILshort antibody (P < 0.05). CONCLUSIONS These results identify TRAILshort in primary human malignancies, and suggest that TRAILshort blockade can augment the effector function of autologous immune effector cells.See related commentary by de Miguel and Pardo, p. 5546.
Collapse
Affiliation(s)
- Fatma Aboulnasr
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
| | - Ashton Krogman
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
| | - Rondell P Graham
- Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota
| | - Nathan W Cummins
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
| | - Anisha Misra
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
| | | | - Jeff R Anderson
- Office of Translation to Practice, Mayo Clinic, Rochester, Minnesota
| | | | | | | | - Zilin Nie
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota
| | - Thomas D Y Chung
- Office of Translation to Practice, Mayo Clinic, Rochester, Minnesota
| | | | | | - Rebecca L King
- Division of Hematopathology, Mayo Clinic, Rochester, Minnesota
| | - Anne J Novak
- Division of Hematology, Mayo Clinic, Rochester, Minnesota
| | | | - Saad Kenderian
- Division of Hematology, Mayo Clinic, Rochester, Minnesota
- Department of Immunology, Mayo Clinic, Rochester, Minnesota
- Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Andrew D Badley
- Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota.
- Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|
4
|
Pinkerton AB, Peddibhotla S, Yamamoto F, Slosky LM, Bai Y, Maloney P, Hershberger P, Hedrick MP, Falter B, Ardecky RJ, Smith LH, Chung TDY, Jackson MR, Caron MG, Barak LS. Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators. J Med Chem 2019; 62:8357-8363. [PMID: 31390201 PMCID: PMC7003992 DOI: 10.1021/acs.jmedchem.9b00340] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator. Neurotensin receptors have been implicated in a wide variety of CNS disorders, but despite extensive efforts to develop small molecule ligands there are few reports of such compounds. Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553), a potent and brain penetrant NTR1 allosteric modulator.
Collapse
Affiliation(s)
- Anthony B. Pinkerton
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Satyamaheshwar Peddibhotla
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Fusayo Yamamoto
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Lauren M. Slosky
- Duke University Medical Center, Durham, North Carolina 27709, United States
| | - Yushi Bai
- Duke University Medical Center, Durham, North Carolina 27709, United States
| | - Patrick Maloney
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Paul Hershberger
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Michael P. Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Bekhi Falter
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Robert J. Ardecky
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Layton H. Smith
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Thomas D. Y. Chung
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Michael R. Jackson
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States
| | - Marc G. Caron
- Duke University Medical Center, Durham, North Carolina 27709, United States
| | - Lawrence S. Barak
- Duke University Medical Center, Durham, North Carolina 27709, United States
| |
Collapse
|
5
|
Anderson JR, Chung TDY, Clark L, Weis JA, Danielsen AJ, Khosla S, Gores GJ, Badley AD. Translation to Practice: Accelerating the Cycle of Innovation to Impact. Mayo Clin Proc 2019; 94:490-499. [PMID: 30738605 PMCID: PMC6853057 DOI: 10.1016/j.mayocp.2018.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 06/04/2018] [Accepted: 08/14/2018] [Indexed: 10/27/2022]
Abstract
The Office of Translation to Practice (OTP) is housed in the Center for Clinical and Translational Sciences at Mayo Clinic. Established in 2015, the office was tasked with developing and managing novel tools, mechanisms, and processes to facilitate and accelerate the translation of products, such as drugs, biological agents, and medical devices, into practice. Since its inception, the OTP is credited with creating valuable services through several strategic alliances and active scientific and project management involvement. The OTP continues to move forward to assist Mayo Clinic physicians and scientists to interact effectively with internal and external collaborators to advance translational projects that will benefit patients. Best practices, innovations, and nascent successes of the OTP are presented and discussed herein.
Collapse
Affiliation(s)
- Jeff R Anderson
- Office of Translation to Practice, Mayo Clinic, Rochester, MN; Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN
| | - Thomas D Y Chung
- Translational Programs Outreach, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
| | | | | | | | - Sundeep Khosla
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN
| | | | - Andrew D Badley
- Office of Translation to Practice, Mayo Clinic, Rochester, MN; Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN; Research Administration; Department of Medicine, Mayo Clinic, Rochester, MN.
| |
Collapse
|
6
|
Li YJ, Du L, Wang J, Vega R, Lee TD, Miao Y, Aldana-Masangkay G, Samuels ER, Li B, Ouyang SX, Colayco SA, Bobkova EV, Divlianska DB, Sergienko E, Chung TDY, Fakih M, Chen Y. Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chem Biol 2019; 26:278-288.e6. [PMID: 30581133 PMCID: PMC6524651 DOI: 10.1016/j.chembiol.2018.10.026] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2018] [Revised: 08/20/2018] [Accepted: 10/26/2018] [Indexed: 12/24/2022]
Abstract
Ubiquitin-like (Ubl) post-translational modifications are potential targets for therapeutics. However, the only known mechanism for inhibiting a Ubl-activating enzyme is through targeting its ATP-binding site. Here we identify an allosteric inhibitory site in the small ubiquitin-like modifier (SUMO)-activating enzyme (E1). This site was unexpected because both it and analogous sites are deeply buried in all previously solved structures of E1s of ubiquitin-like modifiers (Ubl). The inhibitor not only suppresses SUMO E1 activity, but also enhances its degradation in vivo, presumably due to a conformational change induced by the compound. In addition, the lead compound increased the expression of miR-34b and reduced c-Myc levels in lymphoma and colorectal cancer cell lines and a colorectal cancer xenograft mouse model. Identification of this first-in-class inhibitor of SUMO E1 is a major advance in modulating Ubl modifications for therapeutic aims.
Collapse
Affiliation(s)
- Yi-Jia Li
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Li Du
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Jianghai Wang
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Ramir Vega
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Terry D Lee
- Department of Immunology, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA; Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA, USA
| | - Yunan Miao
- Department of Immunology, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA; Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA, USA
| | - Grace Aldana-Masangkay
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Eric R Samuels
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - Baozong Li
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA
| | - S Xiaohu Ouyang
- SUMO Biosciences, Inc., 2265 E Foothill Boulevard, Pasadena, CA 91107, USA
| | - Sharon A Colayco
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Ekaterina V Bobkova
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Daniela B Divlianska
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA
| | - Marwan Fakih
- Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA
| | - Yuan Chen
- Department of Molecular Medicine, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA; Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA, USA.
| |
Collapse
|
7
|
Nie Z, Aboulnasr F, Natesampillai S, Burke SP, Krogman A, Bren GD, Chung TDY, Anderson JR, Smart MK, Katzmann DJ, Rajagopalan G, Cummins NW, Badley AD. Correction: Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. J Immunol 2018; 201:1599. [PMID: 30006376 DOI: 10.4049/jimmunol.1800867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
8
|
Coussens NP, Sittampalam GS, Guha R, Brimacombe K, Grossman A, Chung TDY, Weidner JR, Riss T, Trask OJ, Auld D, Dahlin JL, Devanaryan V, Foley TL, McGee J, Kahl SD, Kales SC, Arkin M, Baell J, Bejcek B, Gal-Edd N, Glicksman M, Haas JV, Iversen PW, Hoeppner M, Lathrop S, Sayers E, Liu H, Trawick B, McVey J, Lemmon VP, Li Z, McManus O, Minor L, Napper A, Wildey MJ, Pacifici R, Chin WW, Xia M, Xu X, Lal-Nag M, Hall MD, Michael S, Inglese J, Simeonov A, Austin CP. Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery. Clin Transl Sci 2018; 11:461-470. [PMID: 29877628 PMCID: PMC6132369 DOI: 10.1111/cts.12570] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Accepted: 05/14/2018] [Indexed: 12/30/2022] Open
Abstract
The Assay Guidance Manual (AGM) is an eBook of best practices for the design, development, and implementation of robust assays for early drug discovery. Initiated by pharmaceutical company scientists, the manual provides guidance for designing a “testing funnel” of assays to identify genuine hits using high‐throughput screening (HTS) and advancing them through preclinical development. Combined with a workshop/tutorial component, the overall goal of the AGM is to provide a valuable resource for training translational scientists.
Collapse
Affiliation(s)
- Nathan P Coussens
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - G Sitta Sittampalam
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Rajarshi Guha
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Kyle Brimacombe
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Abigail Grossman
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States
| | | | - Terry Riss
- Promega Corporation, Madison, Wisconsin, United States
| | - O Joseph Trask
- PerkinElmer, Inc., Waltham, Massachusetts, United States
| | - Douglas Auld
- Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States
| | - Jayme L Dahlin
- Brigham and Women's Hospital, Boston, Massachusetts, United States
| | | | - Timothy L Foley
- Pfizer Worldwide Research and Development, Groton, Connecticut, United States
| | - James McGee
- Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Steven D Kahl
- Eli Lilly and Company, Indianapolis, Indiana, United States
| | - Stephen C Kales
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Michelle Arkin
- Small Molecule Discovery Center, Department of Pharmaceutical Chemistry, University of California, San Francisco, California, United States
| | - Jonathan Baell
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Bruce Bejcek
- Department of Biological Sciences, Western Michigan University, Kalamazoo, Michigan, United States
| | - Neely Gal-Edd
- MacroGenics, Inc., Rockville, Maryland, United States
| | | | - Joseph V Haas
- Eli Lilly and Company, Indianapolis, Indiana, United States
| | | | - Marilu Hoeppner
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Stacy Lathrop
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Eric Sayers
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Hanguan Liu
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Bart Trawick
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Julie McVey
- National Library of Medicine, National Center for Biotechnology Information, Bethesda, Maryland, United States
| | - Vance P Lemmon
- Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United States
| | - Zhuyin Li
- Bristol-Myers Squibb, Lead Discovery and Optimization, Princeton, New Jersey, United States
| | - Owen McManus
- Q-State Biosciences, Cambridge, Massachusetts, United States
| | - Lisa Minor
- In Vitro Strategies, LLC, Flemington, New Jersey, United States
| | - Andrew Napper
- FLX Bio, Inc., San Francisco, California, United States
| | - Mary Jo Wildey
- Merck Research Laboratories, Kenilworth, New Jersey, United States
| | - Robert Pacifici
- CHDI Management, Inc./CHDI Foundation, Inc., Los Angeles, California, United States
| | - William W Chin
- Harvard Medical School, Boston, Massachusetts, United States
| | - Menghang Xia
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Xin Xu
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Madhu Lal-Nag
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Matthew D Hall
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Sam Michael
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - James Inglese
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Anton Simeonov
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| | - Christopher P Austin
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States
| |
Collapse
|
9
|
Nie Z, Aboulnasr F, Natesampillai S, Burke SP, Krogman A, Bren GD, Chung TDY, Anderson JR, Smart MK, Katzmann DJ, Rajagopalan G, Cummins NW, Badley AD. Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. J Immunol 2018; 200:1110-1123. [PMID: 29263214 PMCID: PMC5808399 DOI: 10.4049/jimmunol.1701113] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 11/28/2017] [Indexed: 12/17/2022]
Abstract
TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
Collapse
Affiliation(s)
- Zilin Nie
- HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905
| | | | | | | | - Ashton Krogman
- HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905
- Department of Immunology, Mayo Clinic, Rochester, MN 55905
| | - Gary D Bren
- HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905
| | - Thomas D Y Chung
- Office of Translation to Practice, Mayo Clinic, Rochester, MN 55905
| | - Jeff R Anderson
- Office of Translation to Practice, Mayo Clinic, Rochester, MN 55905
| | | | - David J Katzmann
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905; and
| | | | | | - Andrew D Badley
- HIV Immunology Laboratory, Mayo Clinic, Rochester, MN 55905;
- Office of Translation to Practice, Mayo Clinic, Rochester, MN 55905
- Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905
| |
Collapse
|
10
|
Stanford SM, Aleshin AE, Zhang V, Ardecky RJ, Hedrick MP, Zou J, Ganji SR, Bliss MR, Yamamoto F, Bobkov AA, Kiselar J, Liu Y, Cadwell GW, Khare S, Yu J, Barquilla A, Chung TDY, Mustelin T, Schenk S, Bankston LA, Liddington RC, Pinkerton AB, Bottini N. Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase. Nat Chem Biol 2017; 13:624-632. [PMID: 28346406 PMCID: PMC5435566 DOI: 10.1038/nchembio.2344] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 01/06/2017] [Indexed: 11/09/2022]
Abstract
Obesity-associated insulin resistance plays a central role in type 2 diabetes. As such, tyrosine phosphatases that dephosphorylate the insulin receptor (IR) are potential therapeutic targets. The low-molecular-weight protein tyrosine phosphatase (LMPTP) is a proposed IR phosphatase, yet its role in insulin signaling in vivo has not been defined. Here we show that global and liver-specific LMPTP deletion protects mice from high-fat diet-induced diabetes without affecting body weight. To examine the role of the catalytic activity of LMPTP, we developed a small-molecule inhibitor with a novel uncompetitive mechanism, a unique binding site at the opening of the catalytic pocket, and an exquisite selectivity over other phosphatases. This inhibitor is orally bioavailable, and it increases liver IR phosphorylation in vivo and reverses high-fat diet-induced diabetes. Our findings suggest that LMPTP is a key promoter of insulin resistance and that LMPTP inhibitors would be beneficial for treating type 2 diabetes.
Collapse
Affiliation(s)
- Stephanie M Stanford
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.,Department of Medicine, University of California, San Diego, La Jolla, California, USA
| | - Alexander E Aleshin
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Vida Zhang
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.,Department of Medicine, University of California, San Diego, La Jolla, California, USA
| | - Robert J Ardecky
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Michael P Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Jiwen Zou
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Santhi R Ganji
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Matthew R Bliss
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
| | - Fusayo Yamamoto
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Andrey A Bobkov
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Janna Kiselar
- Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA
| | - Yingge Liu
- Institute for Genetic Medicine, University of Southern California, Los Angeles, California, USA
| | - Gregory W Cadwell
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Shilpi Khare
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Jinghua Yu
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Antonio Barquilla
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Tomas Mustelin
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA
| | - Simon Schenk
- Department of Orthopaedic Surgery and Department of Pediatrics, University of California, San Diego, La Jolla, California, USA
| | - Laurie A Bankston
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Robert C Liddington
- Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Anthony B Pinkerton
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Nunzio Bottini
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.,Department of Medicine, University of California, San Diego, La Jolla, California, USA
| |
Collapse
|
11
|
Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, Carter KP, Colayco S, Magnuson G, Brown B, Nguyen K, Vasile S, Suyama E, Smith LH, Sergienko E, Pinkerton AB, Chung TDY, Palmer AE, Pass I, Hess S, Cohen SM, Deshaies RJ. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol 2017; 13:486-493. [PMID: 28244987 DOI: 10.1038/nchembio.2326] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 01/23/2017] [Indexed: 12/28/2022]
Abstract
The proteasome is a vital cellular machine that maintains protein homeostasis, which is of particular importance in multiple myeloma and possibly other cancers. Targeting of proteasome 20S peptidase activity with bortezomib and carfilzomib has been widely used to treat myeloma. However, not all patients respond to these compounds, and those who do eventually suffer relapse. Therefore, there is an urgent and unmet need to develop new drugs that target proteostasis through different mechanisms. We identified quinoline-8-thiol (8TQ) as a first-in-class inhibitor of the proteasome 19S subunit Rpn11. A derivative of 8TQ, capzimin, shows >5-fold selectivity for Rpn11 over the related JAMM proteases and >2 logs selectivity over several other metalloenzymes. Capzimin stabilized proteasome substrates, induced an unfolded protein response, and blocked proliferation of cancer cells, including those resistant to bortezomib. Proteomic analysis revealed that capzimin stabilized a subset of polyubiquitinated substrates. Identification of capzimin offers an alternative path to develop proteasome inhibitors for cancer therapy.
Collapse
Affiliation(s)
- Jing Li
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA
| | - Tanya Yakushi
- Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, California, USA
| | - Francesco Parlati
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA
| | - Andrew L Mackinnon
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA
| | - Christian Perez
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA
| | - Yuyong Ma
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA
| | - Kyle P Carter
- Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, Colorado, USA
| | - Sharon Colayco
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Gavin Magnuson
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Brock Brown
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Kevin Nguyen
- Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute Lake Nona, Orlando, Florida, USA
| | - Stefan Vasile
- Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute Lake Nona, Orlando, Florida, USA
| | - Eigo Suyama
- Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute Lake Nona, Orlando, Florida, USA
| | - Layton H Smith
- Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham Medical Research Institute Lake Nona, Orlando, Florida, USA
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Anthony B Pinkerton
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Amy E Palmer
- Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, Colorado, USA
| | - Ian Pass
- Conrad Prebys Center for Chemical Genomics at Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - Sonja Hess
- Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, California, USA
| | - Seth M Cohen
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA
| | - Raymond J Deshaies
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.,Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California, USA
| |
Collapse
|
12
|
Abstract
Encoding technology has allowed for the creation of libraries of 50,000 or more low-molecular-weight compounds for biological testing. The current challenge is to properly and efficiently screen among these compounds for useful biological activities. In this example, actives against two related G-protein coupled receptors were sought from a combinatorial library of 56,000 members. The library was synthesized on solid phase using the split synthesis method and photochemically released for testing. At a screening concentration of 0.5-1 /LM, 86 unique structures were identified as active against one receptor and 24 were active against the other. Due to the random nature of compound sampling, five library equivalents or 280,000 beads were screened to ensure greater than 99% representation of library members. As a result, many actives appeared multiple times in the screen, verifying the encoding process. Further confirmation was obtained by resynthesis and testing of predicted active structures. A clear bias for specific "R" groups at each point of variation in the combinatorial library with little overlap between the two receptors has produced a clear structure-activity relationship on which to base further work.
Collapse
Affiliation(s)
- Kenneth C. Appell
- Phanmacopeia, Inc., 101 College Rd. East, Princeton, New Jersey 08540
| | | | | | - Nolan H. Sigal
- Phanmacopeia, Inc., 101 College Rd. East, Princeton, New Jersey 08540
| | - John J. Baldwin
- Phanmacopeia, Inc., 101 College Rd. East, Princeton, New Jersey 08540
| | - Daniel Chelsky
- Phanmacopeia, Inc., 101 College Rd. East, Princeton, New Jersey 08540
| |
Collapse
|
13
|
Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TDY, She ZG, Sugahara KN, Yliperttula M, Wu B, Pellecchia M, Ruoslahti E, Teesalu T. New p32/gC1qR Ligands for Targeted Tumor Drug Delivery. Chembiochem 2016; 17:570-5. [PMID: 26895508 DOI: 10.1002/cbic.201500564] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Indexed: 11/08/2022]
Abstract
Cell surface p32, the target of LyP-1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP-1-mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization-based high-throughput screening of a 50,000-compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface-functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32-expressing breast tumors in mice. This compound provides a lead for the development of p32-targeted affinity ligands that circumvent some of the limitations of peptide-based probes in guided drug delivery.
Collapse
Affiliation(s)
- Lauri Paasonen
- University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, Viikinkaari 5E, Helsinki, 00014, Finland.,Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Shweta Sharma
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Gary B Braun
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Venkata Ramana Kotamraju
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA.,Sanford Burnham Prebys Medical Discovery Institute Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Thomas D Y Chung
- Sanford Burnham Prebys Medical Discovery Institute, Conrad Prebys Center for Chemical Genomics, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Zhi-Gang She
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Kazuki N Sugahara
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA.,Department of Surgery, Columbia University College of Physicians and Surgeons, 1130 St Nicholas Avenue, Suite 217C, New York, NY, 100032, USA
| | - Marjo Yliperttula
- University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, Viikinkaari 5E, Helsinki, 00014, Finland
| | - Bainan Wu
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA
| | - Maurizio Pellecchia
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA.,School of Medicine, University of California, Riverside, Riverside, CA, 92521, USA
| | - Erkki Ruoslahti
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA.,Sanford Burnham Prebys Medical Discovery Institute Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA
| | - Tambet Teesalu
- Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027, USA. .,Sanford Burnham Prebys Medical Discovery Institute Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, 93106, USA. .,Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
| |
Collapse
|
14
|
Roy S, Šileikytė J, Neuenswander B, Hedrick MP, Chung TDY, Aubé J, Schoenen FJ, Forte MA, Bernardi P. N-Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem 2015; 11:283-8. [PMID: 26693836 DOI: 10.1002/cmdc.201500545] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Indexed: 12/21/2022]
Abstract
Persistent opening of the mitochondrial permeability transition pore (PTP), an inner membrane channel, leads to mitochondrial dysfunction and renders the PTP a therapeutic target for a host of life-threatening diseases. Herein, we report our effort toward identifying small-molecule inhibitors of this target through structure-activity relationship optimization studies, which led to the identification of several potent analogues around the N-phenylbenzamide compound series identified by high-throughput screening. In particular, compound 4 (3-(benzyloxy)-5-chloro-N-(4-(piperidin-1-ylmethyl)phenyl)benzamide) displayed noteworthy inhibitory activity in the mitochondrial swelling assay (EC50 =280 nm), poor-to-very-good physicochemical as well as in vitro pharmacokinetic properties, and conferred very high calcium retention capacity to mitochondria. From the data, we believe compound 4 in this series represents a promising lead for the development of PTP inhibitors of pharmacological relevance.
Collapse
Affiliation(s)
- Sudeshna Roy
- University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, KS, 66049, USA. .,Division of Chemical Biology and Medicinal Chemistry and the Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
| | - Justina Šileikytė
- CNR Neuroscience Institute and Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, Padova, 35131, Italy
| | - Benjamin Neuenswander
- University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, KS, 66049, USA
| | - Michael P Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, 10901 N. Torrey Pines Road, La Jolla, CA, 92037, USA
| | - Thomas D Y Chung
- Office of Translation to Practice, Mayo Clinic, Rochester, MN, 55905, USA
| | - Jeffrey Aubé
- University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, KS, 66049, USA
| | - Frank J Schoenen
- University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, KS, 66049, USA.
| | - Michael A Forte
- Vollum Institute, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, 97239, USA.
| | - Paolo Bernardi
- CNR Neuroscience Institute and Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 58/B, Padova, 35131, Italy.
| |
Collapse
|
15
|
Roy S, Šileikytė J, Schiavone M, Neuenswander B, Argenton F, Aubé J, Hedrick MP, Chung TDY, Forte MA, Bernardi P, Schoenen FJ. Discovery, Synthesis, and Optimization of Diarylisoxazole-3-carboxamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore. ChemMedChem 2015; 10:1655-71. [PMID: 26286375 DOI: 10.1002/cmdc.201500284] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Indexed: 01/23/2023]
Abstract
The mitochondrial permeability transition pore (mtPTP) is a Ca(2+) -requiring mega-channel which, under pathological conditions, leads to the deregulated release of Ca(2+) and mitochondrial dysfunction, ultimately resulting in cell death. Although the mtPTP is a potential therapeutic target for many human pathologies, its potential as a drug target is currently unrealized. Herein we describe an optimization effort initiated around hit 1, 5-(3-hydroxyphenyl)-N-(3,4,5-trimethoxyphenyl)isoxazole-3-carboxamide, which was found to possess promising inhibitory activity against mitochondrial swelling (EC50 <0.39 μM) and showed no interference on the inner mitochondrial membrane potential (rhodamine 123 uptake EC50 >100 μM). This enabled the construction of a series of picomolar mtPTP inhibitors that also potently increase the calcium retention capacity of the mitochondria. Finally, the therapeutic potential and in vivo efficacy of one of the most potent analogues, N-(3-chloro-2-methylphenyl)-5-(4-fluoro-3-hydroxyphenyl)isoxazole-3-carboxamide (60), was validated in a biologically relevant zebrafish model of collagen VI congenital muscular dystrophies.
Collapse
Affiliation(s)
- Sudeshna Roy
- University of Kansas Specialized Chemistry Center, 2304 Becker Drive, Lawrence, KS 66049 (USA)
| | - Justina Šileikytė
- CNR Neuroscience Institute and Department of Biomedical Sciences, University of Padova, Padova, 35131 (Italy)
| | - Marco Schiavone
- CNR Neuroscience Institute and Department of Biomedical Sciences, University of Padova, Padova, 35131 (Italy)
| | - Benjamin Neuenswander
- University of Kansas Specialized Chemistry Center, 2304 Becker Drive, Lawrence, KS 66049 (USA)
| | | | - Jeffrey Aubé
- University of Kansas Specialized Chemistry Center, 2304 Becker Drive, Lawrence, KS 66049 (USA)
| | - Michael P Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037 (USA)
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037 (USA)
| | - Michael A Forte
- Vollum Institute, Oregon Health & Science University, Portland, OR 97239 (USA).
| | - Paolo Bernardi
- CNR Neuroscience Institute and Department of Biomedical Sciences, University of Padova, Padova, 35131 (Italy).
| | - Frank J Schoenen
- University of Kansas Specialized Chemistry Center, 2304 Becker Drive, Lawrence, KS 66049 (USA).
| |
Collapse
|
16
|
Schreiber SL, Kotz JD, Li M, Aubé J, Austin CP, Reed JC, Rosen H, White EL, Sklar LA, Lindsley CW, Alexander BR, Bittker JA, Clemons PA, de Souza A, Foley MA, Palmer M, Shamji AF, Wawer MJ, McManus O, Wu M, Zou B, Yu H, Golden JE, Schoenen FJ, Simeonov A, Jadhav A, Jackson MR, Pinkerton AB, Chung TDY, Griffin PR, Cravatt BF, Hodder PS, Roush WR, Roberts E, Chung DH, Jonsson CB, Noah JW, Severson WE, Ananthan S, Edwards B, Oprea TI, Conn PJ, Hopkins CR, Wood MR, Stauffer SR, Emmitte KA. Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell 2015; 161:1252-65. [PMID: 26046436 PMCID: PMC4564295 DOI: 10.1016/j.cell.2015.05.023] [Citation(s) in RCA: 118] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Indexed: 02/06/2023]
Abstract
Small-molecule probes can illuminate biological processes and aid in the assessment of emerging therapeutic targets by perturbing biological systems in a manner distinct from other experimental approaches. Despite the tremendous promise of chemical tools for investigating biology and disease, small-molecule probes were unavailable for most targets and pathways as recently as a decade ago. In 2005, the NIH launched the decade-long Molecular Libraries Program with the intent of innovating in and broadening access to small-molecule science. This Perspective describes how novel small-molecule probes identified through the program are enabling the exploration of biological pathways and therapeutic hypotheses not otherwise testable. These experiences illustrate how small-molecule probes can help bridge the chasm between biological research and the development of medicines but also highlight the need to innovate the science of therapeutic discovery.
Collapse
Affiliation(s)
- Stuart L Schreiber
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | - Joanne D Kotz
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | - Min Li
- Johns Hopkins School of Medicine Ion Channel Center, Baltimore, MD 21205, USA
| | - Jeffrey Aubé
- University of Kansas Specialized Chemistry Center, Lawrence, KS 66045, USA; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, 66045, USA
| | - Christopher P Austin
- NIH Chemical Genomics Center, National Institutes of Health, Rockville, MD 20850, USA; National Center for Advancing Translational Sciences, Bethesda, MD 20892, USA
| | - John C Reed
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, and Lake Nona, FL 32827, USA
| | - Hugh Rosen
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA; Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, 92037, USA
| | - E Lucile White
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - Larry A Sklar
- University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA
| | - Craig W Lindsley
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Benjamin R Alexander
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Joshua A Bittker
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Development of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Paul A Clemons
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Andrea de Souza
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Michael A Foley
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Michelle Palmer
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Alykhan F Shamji
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Mathias J Wawer
- Probe Development Center, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Center for the Science of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Owen McManus
- Johns Hopkins School of Medicine Ion Channel Center, Baltimore, MD 21205, USA
| | - Meng Wu
- Johns Hopkins School of Medicine Ion Channel Center, Baltimore, MD 21205, USA
| | - Beiyan Zou
- Johns Hopkins School of Medicine Ion Channel Center, Baltimore, MD 21205, USA
| | - Haibo Yu
- Johns Hopkins School of Medicine Ion Channel Center, Baltimore, MD 21205, USA
| | - Jennifer E Golden
- University of Kansas Specialized Chemistry Center, Lawrence, KS 66045, USA
| | - Frank J Schoenen
- University of Kansas Specialized Chemistry Center, Lawrence, KS 66045, USA
| | - Anton Simeonov
- NIH Chemical Genomics Center, National Institutes of Health, Rockville, MD 20850, USA; National Center for Advancing Translational Sciences, Bethesda, MD 20892, USA
| | - Ajit Jadhav
- NIH Chemical Genomics Center, National Institutes of Health, Rockville, MD 20850, USA; National Center for Advancing Translational Sciences, Bethesda, MD 20892, USA
| | - Michael R Jackson
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, and Lake Nona, FL 32827, USA
| | - Anthony B Pinkerton
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, and Lake Nona, FL 32827, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, and Lake Nona, FL 32827, USA
| | - Patrick R Griffin
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, 33458, USA
| | - Benjamin F Cravatt
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA; Department of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, 92037, USA
| | - Peter S Hodder
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA
| | - William R Roush
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA; Department of Chemistry, The Scripps Research Institute, Jupiter, FL, 33458, USA
| | - Edward Roberts
- Molecular Screening Center, The Scripps Research Institute, La Jolla, CA 92037, and Jupiter, FL 33458, USA
| | - Dong-Hoon Chung
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - Colleen B Jonsson
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - James W Noah
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - William E Severson
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - Subramaniam Ananthan
- Southern Research Specialized Biocontainment Screening Center, Southern Research Institute, Birmingham, AL 35205, USA
| | - Bruce Edwards
- University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA
| | - Tudor I Oprea
- University of New Mexico Center for Molecular Discovery, Albuquerque, NM 87131, USA; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, 87131, USA
| | - P Jeffrey Conn
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Corey R Hopkins
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Michael R Wood
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| | - Shaun R Stauffer
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Kyle A Emmitte
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA
| |
Collapse
|
17
|
Chung TDY. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models. Comb Chem High Throughput Screen 2015; 17:272-89. [PMID: 24409951 DOI: 10.2174/1386207317666140109124735] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Revised: 11/25/2013] [Accepted: 11/26/2013] [Indexed: 11/22/2022]
Abstract
There has been increased concern that the current "blockbuster" model of drug discovery and development practiced by "Big Pharma" are unsustainable in terms of cost (> $1 billion/approved drug) and time to market (10 - 15 years). The recent mergers and acquisitions (M&A), shuttering of internal research programs, closure of "redundant" sites of operations, senior management turnover and continued workforce reductions among the top 10 major pharmaceutical companies reflect draconian responses to reduce costs. However, the resultant exodus of intellectual capital, loss in motivation and momentum, and exit from early stage discovery programs by pharmaceutical companies has contributed to an "innovation deficit". Disease advocacy groups, investment communities and the government are calling for new innovative business models to address this deficit. In particular they are looking towards academia and clinical trials centers to catalyze new innovations in translational research. Indeed over the last decade many academic institutions have launched drug discovery centers largely comprising high-throughput screening (HTS) to accelerate "translational" research. A major impetus for this "open innovation" effort has been the National Institutes of Health (NIH) "Roadmap" and Molecular Libraries Initiative/Program (MLI/MLP), which is in its last year, and will be transitioned into the National Center for the Advancement of Translational Sciences (NCATS). With the end of Roadmap funding, general reduction in Federal government funding and its recent sequestration, academic drug discovery centers are being challenged to become selfsustaining, adding financial value, while remaining aligned with the missions of their respective academic non-profit institutions. We describe herein, a brief history of our bi-coastal Conrad Prebys Center for Chemical Genomics (Prebys Center) at the Sanford|Burnham Medical Research Institute (SBMRI), the key components of its infrastructure, core competencies of its fully integrated drug discovery expertise, best practices adopted in our day-to-day operations, and finally some of our current funding and collaboration and/or strategic alliance models for pre-competitive drug discovery with other academic/clinical partners, other governmental agencies, and with pharmaceutical and biotechnology companies.
Collapse
Affiliation(s)
- Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, 10901 North Torrey Pines Road, Bldg 2, La Jolla, CA 92037, USA.
| |
Collapse
|
18
|
Musumeci L, Kuijpers MJ, Gilio K, Hego A, Théâtre E, Maurissen L, Vandereyken M, Diogo CV, Lecut C, Guilmain W, Bobkova EV, Eble JA, Dahl R, Drion P, Rascon J, Mostofi Y, Yuan H, Sergienko E, Chung TDY, Thiry M, Senis Y, Moutschen M, Mustelin T, Lancellotti P, Heemskerk JWM, Tautz L, Oury C, Rahmouni S. Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis. Circulation 2014; 131:656-68. [PMID: 25520375 DOI: 10.1161/circulationaha.114.010186] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. A better understanding of the molecular mechanisms leading to platelet activation is important for the development of improved therapies. Recently, protein tyrosine phosphatases have emerged as critical regulators of platelet function. METHODS AND RESULTS This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated by the collagen receptor glycoprotein VI and the C-type lectin-like receptor 2. DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism compared with wild-type mice and showed severely impaired thrombus formation on ferric chloride-induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of phospholipase Cγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen- and C-type lectin-like receptor 2-induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells. CONCLUSIONS DUSP3 plays a selective and essential role in collagen- and C-type lectin-like receptor 2-mediated platelet activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is the first time a protein tyrosine phosphatase, implicated in platelet signaling, has been targeted with a small-molecule drug.
Collapse
Affiliation(s)
- Lucia Musumeci
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Marijke J Kuijpers
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Karen Gilio
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Alexandre Hego
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Emilie Théâtre
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Lisbeth Maurissen
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Maud Vandereyken
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Catia V Diogo
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Christelle Lecut
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - William Guilmain
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Ekaterina V Bobkova
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Johannes A Eble
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Russell Dahl
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Pierre Drion
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Justin Rascon
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Yalda Mostofi
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Hongbin Yuan
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Eduard Sergienko
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Thomas D Y Chung
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Marc Thiry
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Yotis Senis
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Michel Moutschen
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Tomas Mustelin
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Patrizio Lancellotti
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Johan W M Heemskerk
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.)
| | - Lutz Tautz
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.).
| | - Cécile Oury
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.).
| | - Souad Rahmouni
- From the Immunology and Infectious Diseases Unit, GIGA-Signal Transduction (L. Musumeci, L. Maurissen, M.V., C.V.D., M.M., S.R.), Laboratory of Thrombosis and Haemostasis, GIGA-Cardiovascular Sciences (A.H., L. Maurissen, C.V.D., C.L., W.G., C.O.), Unit of Animal Genomics, GIGA-Genetics and Faculty of Veterinary Medicine (E.T.), Unit of Hepato-Gastroenterology, CHU de Liège and Faculty of Medicine (E.T.), GIGA-Animal Facility (B23) (P.D.), Laboratory of Cell and Tissue Biology, GIGA-Neurosciences (M.T.), and Department of Cardiology, Heart Valve Clinic, CHU Sart Tilman, GIGA Cardiovascular Sciences (P.L.), University of Liège, Liège, Belgium; Laboratory of Cellular Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht CARIM, Maastricht University, Maastricht, the Netherlands (M.J.K., K.G., L. Maurissen, J.W.M.H.); Conrad Prebys Center for Chemical Genomics (E.V.B., R.D., J.R., Y.M., H.Y., E.S., T.D.Y.C.) and NCI-Designated Cancer Center (L.T.), Sanford-Burnham Medical Research Institute, La Jolla, CA; Institute for Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany (J.A.E.); and Centre for Cardiovascular Sciences, Institute of Biomedical Research, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK (Y.S.).
| |
Collapse
|
19
|
Flaherty DP, Miller JR, Garshott DM, Hedrick M, Gosalia P, Li Y, Milewski M, Sugarman E, Vasile S, Salaniwal S, Su Y, Smith LH, Chung TDY, Pinkerton AB, Aubé J, Callaghan MU, Golden JE, Fribley AM, Kaufman RJ. Discovery of Sulfonamidebenzamides as Selective Apoptotic CHOP Pathway Activators of the Unfolded Protein Response. ACS Med Chem Lett 2014; 5:1278-1283. [PMID: 25530830 PMCID: PMC4266338 DOI: 10.1021/ml5003234] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Accepted: 10/29/2014] [Indexed: 01/29/2023] Open
Abstract
![]()
Cellular proteins that fail to fold
properly result in inactive
or disfunctional proteins that can have toxic functions. The unfolded
protein response (UPR) is a two-tiered cellular mechanism initiated
by eukaryotic cells that have accumulated misfolded proteins within
the endoplasmic reticulum (ER). An adaptive pathway facilitates the
clearance of the undesired proteins; however, if overwhelmed, cells
trigger apoptosis by upregulating transcription factors such as C/EBP-homologous
protein (CHOP). A high throughput screen was performed directed at
identifying compounds that selectively upregulate the apoptotic CHOP
pathway while avoiding adaptive signaling cascades, resulting in a
sulfonamidebenzamide chemotype that was optimized. These efforts produced
a potent and selective CHOP inducer (AC50 = 0.8 μM;
XBP1 > 80 μM), which was efficacious in both mouse embryonic
fibroblast cells and a human oral squamous cell cancer cell line,
and demonstrated antiproliferative effects for multiple cancer cell
lines in the NCI-60 panel.
Collapse
Affiliation(s)
- Daniel P. Flaherty
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Justin R. Miller
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Danielle M. Garshott
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Michael Hedrick
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Palak Gosalia
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Yujie Li
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Monika Milewski
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Eliot Sugarman
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Stefan Vasile
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Sumeet Salaniwal
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Ying Su
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Layton H. Smith
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Thomas D. Y. Chung
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Anthony B. Pinkerton
- Conrad
Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La
Jolla, California 92037, United States
| | - Jeffrey Aubé
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Michael U. Callaghan
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Jennifer E. Golden
- Delbert
M. Shankel Structural Biology Center, University of Kansas Specialized Chemistry Center, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Andrew M. Fribley
- Carmen
and Ann Adams Department of Pediatrics, Division of Hematology and
Oncology, and the Karmanos Cancer Institute Molecular Therapeutics
Group, Wayne State University, 2228 Elliman Building, 421 East
Canfield, Detroit, Michigan 48201, United States
| | - Randal J. Kaufman
- Program
in Degenerative Disease Research, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States
| |
Collapse
|
20
|
Howe EA, de Souza A, Lahr DL, Chatwin S, Montgomery P, Alexander BR, Nguyen DT, Cruz Y, Stonich DA, Walzer G, Rose JT, Picard SC, Liu Z, Rose JN, Xiang X, Asiedu J, Durkin D, Levine J, Yang JJ, Schürer SC, Braisted JC, Southall N, Southern MR, Chung TDY, Brudz S, Tanega C, Schreiber SL, Bittker JA, Guha R, Clemons PA. BioAssay Research Database (BARD): chemical biology and probe-development enabled by structured metadata and result types. Nucleic Acids Res 2014; 43:D1163-70. [PMID: 25477388 DOI: 10.1093/nar/gku1244] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
BARD, the BioAssay Research Database (https://bard.nih.gov/) is a public database and suite of tools developed to provide access to bioassay data produced by the NIH Molecular Libraries Program (MLP). Data from 631 MLP projects were migrated to a new structured vocabulary designed to capture bioassay data in a formalized manner, with particular emphasis placed on the description of assay protocols. New data can be submitted to BARD with a user-friendly set of tools that assist in the creation of appropriately formatted datasets and assay definitions. Data published through the BARD application program interface (API) can be accessed by researchers using web-based query tools or a desktop client. Third-party developers wishing to create new tools can use the API to produce stand-alone tools or new plug-ins that can be integrated into BARD. The entire BARD suite of tools therefore supports three classes of researcher: those who wish to publish data, those who wish to mine data for testable hypotheses, and those in the developer community who wish to build tools that leverage this carefully curated chemical biology resource.
Collapse
Affiliation(s)
- E A Howe
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - A de Souza
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - D L Lahr
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - S Chatwin
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - P Montgomery
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - B R Alexander
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - D-T Nguyen
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), 9800 Medical Center Drive, Rockville, MD 20850, USA
| | - Y Cruz
- The Translational Research Institute, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA
| | - D A Stonich
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - G Walzer
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J T Rose
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - S C Picard
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - Z Liu
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J N Rose
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - X Xiang
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J Asiedu
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - D Durkin
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J Levine
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J J Yang
- University of New Mexico Center for Molecular Discovery, University of New Mexico Health Sciences Center, 2500 Marble Avenue NE, Albuquerque, NM 87131, USA
| | - S C Schürer
- Center for Computational Science, University of Miami, 1320 S. Dixie Highway, Gables One Tower, Coral Gables, FL 33146, USA
| | - J C Braisted
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), 9800 Medical Center Drive, Rockville, MD 20850, USA
| | - N Southall
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), 9800 Medical Center Drive, Rockville, MD 20850, USA
| | - M R Southern
- The Translational Research Institute, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA
| | - T D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA
| | - S Brudz
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - C Tanega
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), 9800 Medical Center Drive, Rockville, MD 20850, USA
| | - S L Schreiber
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - J A Bittker
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| | - R Guha
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), 9800 Medical Center Drive, Rockville, MD 20850, USA
| | - P A Clemons
- Center for the Science of Therapeutics, Broad Institute, 415 Main Street, Cambridge, MA 02142, USA
| |
Collapse
|
21
|
de Souza A, Bittker JA, Lahr DL, Brudz S, Chatwin S, Oprea TI, Waller A, Yang JJ, Southall N, Guha R, Schürer SC, Vempati UD, Southern MR, Dawson ES, Clemons PA, Chung TDY. An Overview of the Challenges in Designing, Integrating, and Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and Disciplines. ACTA ACUST UNITED AC 2014; 19:614-27. [PMID: 24441647 DOI: 10.1177/1087057113517139] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 11/22/2013] [Indexed: 01/15/2023]
Abstract
Recent industry-academic partnerships involve collaboration among disciplines, locations, and organizations using publicly funded "open-access" and proprietary commercial data sources. These require the effective integration of chemical and biological information from diverse data sources, which presents key informatics, personnel, and organizational challenges. The BioAssay Research Database (BARD) was conceived to address these challenges and serve as a community-wide resource and intuitive web portal for public-sector chemical-biology data. Its initial focus is to enable scientists to more effectively use the National Institutes of Health Roadmap Molecular Libraries Program (MLP) data generated from the 3-year pilot and 6-year production phases of the Molecular Libraries Probe Production Centers Network (MLPCN), which is currently in its final year. BARD evolves the current data standards through structured assay and result annotations that leverage BioAssay Ontology and other industry-standard ontologies, and a core hierarchy of assay definition terms and data standards defined specifically for small-molecule assay data. We initially focused on migrating the highest-value MLP data into BARD and bringing it up to this new standard. We review the technical and organizational challenges overcome by the interdisciplinary BARD team, veterans of public- and private-sector data-integration projects, who are collaborating to describe (functional specifications), design (technical specifications), and implement this next-generation software solution.
Collapse
Affiliation(s)
| | | | - David L Lahr
- Broad Institute of Harvard and MIT, Cambridge, MA, USA
| | - Steve Brudz
- Broad Institute of Harvard and MIT, Cambridge, MA, USA
| | - Simon Chatwin
- Broad Institute of Harvard and MIT, Cambridge, MA, USA
| | - Tudor I Oprea
- University of New Mexico Center for Molecular Discovery, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
| | - Anna Waller
- University of New Mexico Center for Molecular Discovery, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
| | - Jeremy J Yang
- University of New Mexico Center for Molecular Discovery, University of New Mexico Health Sciences Center, Albuquerque, NM, USA
| | - Noel Southall
- NIH Center for Advancing Translational Sciences, Rockville, MD, USA
| | - Rajarshi Guha
- NIH Center for Advancing Translational Sciences, Rockville, MD, USA
| | - Stephan C Schürer
- Center for Computational Science, University of Miami, Miami, FL, USA
| | - Uma D Vempati
- Center for Computational Science, University of Miami, Miami, FL, USA
| | - Mark R Southern
- The Translational Research Institute, The Scripps Research Institute, Jupiter, FL, USA
| | - Eric S Dawson
- The Vanderbilt Specialized Chemistry Center for Accelerated Probe Development, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, La Jolla, CA, USA
| |
Collapse
|
22
|
Ardecky RJ, Bobkova EV, Kiffer-Moreira T, Brown B, Ganji S, Zou J, Pass I, Narisawa S, Iano FG, Rosenstein C, Cheltsov A, Rascon J, Hedrick M, Gasior C, Forster A, Shi S, Dahl R, Vasile S, Su Y, Sergienko E, Chung TDY, Kaunitz J, Hoylaerts MF, Pinkerton AB, Millán JL. Identification of a selective inhibitor of murine intestinal alkaline phosphatase (ML260) by concurrent ultra-high throughput screening against human and mouse isozymes. Bioorg Med Chem Lett 2013; 24:1000-1004. [PMID: 24412070 DOI: 10.1016/j.bmcl.2013.12.043] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 12/06/2013] [Accepted: 12/10/2013] [Indexed: 12/31/2022]
Abstract
Alkaline phosphatase (AP) isozymes are present in a wide range of species from bacteria to man and are capable of dephosphorylation and transphosphorylation of a wide spectrum of substrates in vitro. In humans, four AP isozymes have been identified-one tissue-nonspecific (TNAP) and three tissue-specific-named according to the tissue of their predominant expression: intestinal (IAP), placental (PLAP) and germ cell (GCAP) APs. Modulation of activity of the different AP isozymes may have therapeutic implications in distinct diseases and cellular processes. For instance, changes in the level of IAP activity can affect gut mucosa tolerance to microbial invasion due to the ability of IAP to detoxify bacterial endotoxins, alter the absorption of fatty acids and affect ectopurinergic regulation of duodenal bicarbonate secretion. To identify isozyme selective modulators of the human and mouse IAPs, we developed a series of murine duodenal IAP (Akp3-encoded dIAP isozyme), human IAP (hIAP), PLAP, and TNAP assays. High throughput screening and subsequent SAR efforts generated a potent inhibitor of dIAP, ML260, with specificity for the Akp3-, compared to the Akp5- and Akp6-encoded mouse isozymes.
Collapse
Affiliation(s)
| | | | | | - Brock Brown
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Santhi Ganji
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Jiwen Zou
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Ian Pass
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Sonoko Narisawa
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | | | | | - Anton Cheltsov
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Justin Rascon
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Michael Hedrick
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Carlton Gasior
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Anita Forster
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Shenghua Shi
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | - Russell Dahl
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | | | - Ying Su
- Sanford-Burnham Medical Research Institute, La Jolla, CA 92037
| | | | | | | | - Marc F Hoylaerts
- Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
| | | | | |
Collapse
|
23
|
Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, Heynen-Genel S, Milan LB, Chung TDY, Seltzman HH, Bai Y, Caron MG, Barak LS, Croatt MP, Abood ME, Reggio PH. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 2013; 52:9456-69. [PMID: 24274581 DOI: 10.1021/bi4008885] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
GPR55 is a class A G protein-coupled receptor (GPCR) that has been implicated in inflammatory pain, neuropathic pain, metabolic disorder, bone development, and cancer. Initially deorphanized as a cannabinoid receptor, GPR55 has been shown to be activated by non-cannabinoid ligands such as l-α-lysophosphatidylinositol (LPI). While there is a growing body of evidence of physiological and pathophysiological roles for GPR55, the paucity of specific antagonists has limited its study. In collaboration with the Molecular Libraries Probe Production Centers Network initiative, we identified a series of GPR55 antagonists using a β-arrestin, high-throughput, high-content screen of ~300000 compounds. This screen yielded novel, GPR55 antagonist chemotypes with IC50 values in the range of 0.16-2.72 μM [Heynen-Genel, S., et al. (2010) Screening for Selective Ligands for GPR55: Antagonists (ML191, ML192, ML193) (Bookshelf ID NBK66153; PMID entry 22091481)]. Importantly, many of the GPR55 antagonists were completely selective, with no agonism or antagonism against GPR35, CB1, or CB2 up to 20 μM. Using a model of the GPR55 inactive state, we studied the binding of an antagonist series that emerged from this screen. These studies suggest that GPR55 antagonists possess a head region that occupies a horizontal binding pocket extending into the extracellular loop region, a central ligand portion that fits vertically in the receptor binding pocket and terminates with a pendant aromatic or heterocyclic ring that juts out. Both the region that extends extracellularly and the pendant ring are features associated with antagonism. Taken together, our results provide a set of design rules for the development of second-generation GPR55 selective antagonists.
Collapse
Affiliation(s)
- Evangelia Kotsikorou
- Department of Chemistry, University of Texas-Pan American , Edinburg, Texas 78539, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Hershberger PM, Hedrick MP, Peddibhotla S, Mangravita-Novo A, Gosalia P, Li Y, Gray W, Vicchiarelli M, Smith LH, Chung TDY, Thomas JB, Caron MG, Pinkerton AB, Barak LS, Roth GP. Imidazole-derived agonists for the neurotensin 1 receptor. Bioorg Med Chem Lett 2013; 24:262-7. [PMID: 24332089 DOI: 10.1016/j.bmcl.2013.11.026] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2013] [Revised: 11/06/2013] [Accepted: 11/11/2013] [Indexed: 10/26/2022]
Abstract
A scaffold-hop program seeking full agonists of the neurotensin-1 (NTR1) receptor identified the probe molecule ML301 (1) and associated analogs, including its naphthyl analog (14) which exhibited similar properties. Compound 1 showed full agonist behavior (79-93%) with an EC50 of 2.0-4.1μM against NTR1. Compound 1 also showed good activity in a Ca mobilization FLIPR assay (93% efficacy at 298nM), consistent with it functioning via the Gq coupled pathway, and good selectivity relative to NTR2 and GPR35. In further profiling, 1 showed low potential for promiscuity and good overall pharmacological data. This report describes the discovery, synthesis, and SAR of 1 and associated analogs. Initial in vitro pharmacologic characterization is also presented.
Collapse
Affiliation(s)
- Paul M Hershberger
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA.
| | - Michael P Hedrick
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Satyamaheshwar Peddibhotla
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Arianna Mangravita-Novo
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Palak Gosalia
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Yujie Li
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Wilson Gray
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Michael Vicchiarelli
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Layton H Smith
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - James B Thomas
- RTI International, 3040 E Cornwallis Road, Durham, NC 27709, USA
| | - Marc G Caron
- Duke University Medical Center, Durham, NC 27710, USA
| | - Anthony B Pinkerton
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | | | - Gregory P Roth
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA
| |
Collapse
|
25
|
Stanford SM, Krishnamurthy D, Kulkarni RA, Karver CE, Bruenger E, Walker LM, Ma CT, Chung TDY, Sergienko E, Bottini N, Barrios AM. pCAP-based peptide substrates: the new tool in the box of tyrosine phosphatase assays. Methods 2013; 65:165-74. [PMID: 23886911 DOI: 10.1016/j.ymeth.2013.07.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Revised: 07/10/2013] [Accepted: 07/13/2013] [Indexed: 10/26/2022] Open
Abstract
Robust, facile high throughput assays based on non-peptidic probes are available to detect the enzyme activity of protein tyrosine phosphatases. However, these assays cannot replace the use of peptide-based probes in many applications; for example when a closer mimic of the physiological target is desired or in substrate profiling expeditions. Phosphotyrosine peptides are often used in these assays, but their use is complicated by either poor sensitivity or the need for indirect detection methods, among other pitfalls. Novel peptide-based probes for protein tyrosine phosphatases are needed to replace phosphotyrosine peptides and accelerate the field of tyrosine phosphatase substrate profiling. Here we review a type of peptidic probe for tyrosine phosphatases, which is based on the incorporation of the phosphotyrosine-mimic phosphocoumaryl amino propionic acid (pCAP) into peptides. The resulting fluorogenic pCAP peptides are dephosphorylated by tyrosine phosphatases with similar efficiency as the homologous phosphotyrosine peptides. pCAP peptides outperform phosphotyrosine peptides, providing an assay that is as robust, sensitive and facile as the non-peptidic fluorogenic probes on the market. Finally the use of pCAP can expand the range of phosphatase assays, facilitating the investigation of multiphosphorylated peptides and providing an in-gel assay for phosphatase activity.
Collapse
Affiliation(s)
- Stephanie M Stanford
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
| | - Divya Krishnamurthy
- Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA; Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Rhushikesh A Kulkarni
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Caitlin E Karver
- Department of Chemistry, University of Southern California, Los Angeles, CA 90089, USA; Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Eveline Bruenger
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
| | - Logan M Walker
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA
| | - Chen-Ting Ma
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Thomas D Y Chung
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics, Sanford
- Burnham Medical Research Institute, La Jolla, CA 92037, USA
| | - Nunzio Bottini
- Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
| | - Amy M Barrios
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
| |
Collapse
|
26
|
Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M, Gosalia P, Gray W, Mehta A, Sugarman E, Hood B, Suyama E, Nguyen K, Heynen-Genel S, Vasile S, Salaniwal S, Stonich D, Su Y, Mangravita-Novo A, Vicchiarelli M, Roth GP, Smith LH, Chung TDY, Hanson GR, Thomas JB, Caron MG, Barak LS, Pinkerton AB. Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor. ACS Med Chem Lett 2013; 4:846-851. [PMID: 24611085 DOI: 10.1021/ml400176n] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The neurotensin 1 receptor (NTR1) is an important therapeutic target for a range of disease states including addiction. A high throughput screening campaign, followed by medicinal chemistry optimization, led to the discovery of a non-peptidic β-arrestin biased agonist for NTR1. The lead compound, 2-cyclopropyl-6,7-dimethoxy-4-(4-(2-methoxyphenyl)- piperazin-1-yl)quinazoline, 32 (ML314), exhibits full agonist behavior against NTR1 (EC50 = 2.0 μM) in the primary assay and selectivity against NTR2. The effect of 32 is blocked by the NTR1 antagonist SR142948A in a dose dependent manner. Unlike peptide based NTR1 agonists, compound 32 has no significant response in a Ca2+ mobilization assay and is thus a biased agonist that activates the β-arrestin pathway rather than the traditional G q coupled pathway. This bias has distinct biochemical and functional consequences that may lead to physiological advantages. Compound 32 displays good brain penetration in rodents, and studies examining its in vivo properties are underway.
Collapse
Affiliation(s)
- Satyamaheshwar Peddibhotla
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Michael P. Hedrick
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Paul Hershberger
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Patrick R. Maloney
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Yujie Li
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Monika Milewski
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Palak Gosalia
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Wilson Gray
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Alka Mehta
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Eliot Sugarman
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Becky Hood
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Eigo Suyama
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Kevin Nguyen
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Susanne Heynen-Genel
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Stefan Vasile
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Sumeet Salaniwal
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Derek Stonich
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Ying Su
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Arianna Mangravita-Novo
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Michael Vicchiarelli
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Gregory P. Roth
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Layton H. Smith
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, United States
| | - Thomas D. Y. Chung
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Glen R. Hanson
- Department of Pharmacology and Toxicology, University of Utah, 260 S. Campus Drive, Salt Lake City, Utah 84112, United States
| | - James B. Thomas
- RTI International, 3040 E Cornwallis Road, Durham, North Carolina 27709, United States
| | - Marc G. Caron
- Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Lawrence S. Barak
- Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Anthony B. Pinkerton
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| |
Collapse
|
27
|
Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, Nguyen K, Mehta A, Vasile S, Su Y, Stonich D, Nguyen H, Zeng FY, Mangravita Novo A, Vicchiarelli M, Diwan J, Chung TDY, Smith LH, Pinkerton AB. Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett 2012; 22:6656-60. [PMID: 23010269 PMCID: PMC3729231 DOI: 10.1016/j.bmcl.2012.08.105] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2012] [Revised: 08/23/2012] [Accepted: 08/28/2012] [Indexed: 12/21/2022]
Abstract
The recently discovered apelin/APJ system has emerged as a critical mediator of cardiovascular homeostasis and is associated with the pathogenesis of cardiovascular disease. A role for apelin/APJ in energy metabolism and gastrointestinal function has also recently emerged. We disclose the discovery and characterization of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221), a potent APJ functional antagonist in cell-based assays that is >37-fold selective over the closely related angiotensin II type 1 (AT1) receptor. ML221 was derived from an HTS of the ~330,600 compound MLSMR collection. This antagonist showed no significant binding activity against 29 other GPCRs, except to the κ-opioid and benzodiazepinone receptors (<50/<70%I at 10 μM). The synthetic methodology, development of structure-activity relationship (SAR), and initial in vitro pharmacologic characterization are also presented.
Collapse
Affiliation(s)
- Patrick R. Maloney
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Pasha Khan
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Michael Hedrick
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Palak Gosalia
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Monika Milewski
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Linda Li
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Gregory P. Roth
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Eigo Suyama
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Eliot Sugarman
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Kevin Nguyen
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Alka Mehta
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Stefan Vasile
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Ying Su
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Derek Stonich
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Hung Nguyen
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Fu-Yue Zeng
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Arianna Mangravita Novo
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Michael Vicchiarelli
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Jena Diwan
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Thomas D. Y. Chung
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Layton H. Smith
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 6400 Sanger Road, Orlando, FL 32827, USA
- Cardiopathobiology Program, Diabetes and Obesity Research Center, Sanford Burnham Medical Research Institute at Lake Nona, 6400 Sanger Road, Orlando, FL 32827, USA
| | - Anthony B. Pinkerton
- Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
| |
Collapse
|
28
|
Preuss J, Maloney P, Peddibhotla S, Hedrick MP, Hershberger P, Gosalia P, Milewski M, Li YL, Sugarman E, Hood B, Suyama E, Nguyen K, Vasile S, Sergienko E, Mangravita-Novo A, Vicchiarelli M, McAnally D, Smith LH, Roth GP, Diwan J, Chung TDY, Jortzik E, Rahlfs S, Becker K, Pinkerton AB, Bode L. Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro. J Med Chem 2012; 55:7262-72. [PMID: 22813531 DOI: 10.1021/jm300833h] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A high-throughput screen of the NIH's MLSMR collection of ∼340000 compounds was undertaken to identify compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PD). PfG6PD is important for proliferating and propagating P. falciparum and differs structurally and mechanistically from the human orthologue. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fast-growing cells. In P. falciparum , the bifunctional enzyme glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) catalyzes the first two steps of the PPP. Because P. falciparum and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of PfGluPho. The lead compound identified from this effort, (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide, 11 (ML276), is a submicromolar inhibitor of PfG6PD (IC(50) = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC(50) = 2.6 μM) against P. falciparum in culture, and has good drug-like properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting PfG6PD in vivo are in progress.
Collapse
Affiliation(s)
- Janina Preuss
- Department of Pediatrics, University of California, San Diego, La Jolla, California 92037, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Frankowski KJ, Hedrick MP, Gosalia P, Li K, Shi S, Whipple D, Ghosh P, Prisinzano TE, Schoenen FJ, Su Y, Vasile S, Sergienko E, Gray W, Hariharan S, Milan L, Heynen-Genel S, Mangravita-Novo A, Vicchiarelli M, Smith LH, Streicher JM, Caron MG, Barak LS, Bohn LM, Chung TDY, Aubé J. Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci 2012; 3:221-236. [PMID: 22737280 DOI: 10.1021/cn200128x] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Herein we present the outcome of a high throughput screening (HTS) campaign-based strategy for the rapid identification and optimization of selective and general chemotypes for both kappa (κ) opioid receptor (KOR) activation and inhibition. In this program, we have developed potent antagonists (IC(50) < 120 nM) or agonists of high binding affinity (K(i) < 3 nM). In contrast to many important KOR ligands, the compounds presented here are highly modular, readily synthesized and, in most cases, achiral. The four new chemotypes hold promise for further development into chemical tools for studying the KOR or as potential therapeutic lead candidates.
Collapse
Affiliation(s)
- Kevin J. Frankowski
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Michael P. Hedrick
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Palak Gosalia
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Kelin Li
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Shenghua Shi
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - David Whipple
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Partha Ghosh
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Thomas E. Prisinzano
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Frank J. Schoenen
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| | - Ying Su
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - S. Vasile
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Eduard Sergienko
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Wilson Gray
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Santosh Hariharan
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Loribelle Milan
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Susanne Heynen-Genel
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Arianna Mangravita-Novo
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Michael Vicchiarelli
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - Layton H. Smith
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute at Lake Nona, Orlando, Florida 32827, United States
| | - John M. Streicher
- Department of Molecular
Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458,
United States
| | - Marc G. Caron
- Department of Cell Biology, Duke University, Durham, North Carolina 27710, United
States
| | - Lawrence S. Barak
- Department of Cell Biology, Duke University, Durham, North Carolina 27710, United
States
| | - Laura M. Bohn
- Department of Molecular
Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458,
United States
| | - Thomas D. Y. Chung
- Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States
| | - Jeffrey Aubé
- University of Kansas Specialized
Chemistry Center, University of Kansas,
Lawrence, Kansas 66047, United States
| |
Collapse
|
30
|
Sergienko E, Xu J, Liu WH, Dahl R, Critton DA, Su Y, Brown BT, Chan X, Yang L, Bobkova EV, Vasile S, Yuan H, Rascon J, Colayco S, Sidique S, Cosford NDP, Chung TDY, Mustelin T, Page R, Lombroso PJ, Tautz L. Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation. ACS Chem Biol 2012; 7:367-77. [PMID: 22070201 DOI: 10.1021/cb2004274] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The hematopoietic protein tyrosine phosphatase (HePTP) is implicated in the development of blood cancers through its ability to negatively regulate the mitogen-activated protein kinases (MAPKs) ERK1/2 and p38. Small-molecule modulators of HePTP activity may become valuable in treating hematopoietic malignancies such as T cell acute lymphoblastic leukemia (T-ALL) and acute myelogenous leukemia (AML). Moreover, such compounds will further elucidate the regulation of MAPKs in hematopoietic cells. Although transient activation of MAPKs is crucial for growth and proliferation, prolonged activation of these important signaling molecules induces differentiation, cell cycle arrest, cell senescence, and apoptosis. Specific HePTP inhibitors may promote the latter and thereby may halt the growth of cancer cells. Here, we report the development of a small molecule that augments ERK1/2 and p38 activation in human T cells, specifically by inhibiting HePTP. Structure-activity relationship analysis, in silico docking studies, and mutagenesis experiments reveal how the inhibitor achieves selectivity for HePTP over related phosphatases by interacting with unique amino acid residues in the periphery of the highly conserved catalytic pocket. Importantly, we utilize this compound to show that pharmacological inhibition of HePTP not only augments but also prolongs activation of ERK1/2 and, especially, p38. Moreover, we present similar effects in leukocytes from mice intraperitoneally injected with the inhibitor at doses as low as 3 mg/kg. Our results warrant future studies with this probe compound that may establish HePTP as a new drug target for acute leukemic conditions.
Collapse
Affiliation(s)
| | | | | | | | - David A. Critton
- Department
of Molecular Biology,
Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Rebecca Page
- Department
of Molecular Biology,
Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, United States
| | | | | |
Collapse
|
31
|
Zhai D, Godoi P, Sergienko E, Dahl R, Chan X, Brown B, Rascon J, Hurder A, Su Y, Chung TDY, Jin C, Diaz P, Reed JC. High-throughput fluorescence polarization assay for chemical library screening against anti-apoptotic Bcl-2 family member Bfl-1. ACTA ACUST UNITED AC 2011; 17:350-60. [PMID: 22156224 DOI: 10.1177/1087057111429372] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Overexpression of the anti-apoptotic Bcl-2 family proteins occurs commonly in human cancers. Bfl-1 is highly expressed in some types of malignant cells, contributing significantly to tumor cell survival and chemoresistance. Therefore, it would be desirable to have chemical antagonists of Bfl-1. To this end, we devised a fluorescence polarization assay (FPA) using Bfl-1 protein and fluorescein-conjugated Bid BH3 peptide, which was employed for high-throughput screening of chemical libraries. Approximately 66 000 compounds were screened for the ability to inhibit BH3 peptide binding to Bfl-1, yielding 14 reproducible hits with ≥50% displacement. After dose-response analysis and confirmation using a secondary assay based on time-resolved fluorescence resonance energy transfer (TR-FRET), two groups of Bfl-1-specific inhibitors were identified, including chloromaleimide and sulfonylpyrimidine series compounds. FPAs generated for each of the six anti-apoptotic Bcl-2 proteins demonstrated selective binding of both classes of compounds to Bfl-1. Analogs of the sulfonylpyrimidine series were synthesized and compared with the original hit for Bfl-1 binding by both FPAs and TR-FRET assays. The resulting structure-activity relation analysis led to the chemical probe compound CID-2980973 (ML042). Collectively, these findings demonstrate the feasibility of using the HTS assay for discovery of selective chemical inhibitors of Bfl-1.
Collapse
Affiliation(s)
- Dayong Zhai
- Sanford-Burnham Medical Research Institute, Program on Apoptosis and Cell Death Research, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Bobkova EV, Liu WH, Colayco S, Rascon J, Vasile S, Gasior C, Critton DA, Chan X, Dahl R, Su Y, Sergienko E, Chung TDY, Mustelin T, Page R, Tautz L. Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids. ACS Med Chem Lett 2011; 2:113-118. [PMID: 21503265 DOI: 10.1021/ml100103p] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Protein tyrosine phosphatases (PTPs) have only recently become the focus of attention in the search for novel drug targets despite the fact that they play vital roles in numerous cellular processes and are implicated in many human diseases. The hematopoietic protein tyrosine phosphatase (HePTP) is often found dysregulated in preleukemic myelodysplastic syndrome (MDS), as well as in acute myelogenous leukemia (AML). Physiological substrates of HePTP include the mitogen-activated protein kinases (MAPKs) ERK1/2 and p38. Specific modulators of HePTP catalytic activity will be useful for elucidating mechanisms of MAPK regulation in hematopietic cells, and may also provide treatments for hematopoietic malignancies such as AML. Here we report the discovery of phenoxyacetic acids as inhibitors of HePTP. Structure-activity relationship (SAR) analysis and in silico docking studies reveal the molecular basis of HePTP inhibition by these compounds. We also show that these compounds are able to penetrate cell membranes and inhibit HePTP in human T lymphocytes.
Collapse
Affiliation(s)
| | | | | | | | | | | | - David A. Critton
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, United States
| | | | | | - Ying Su
- Conrad Prebys Center for Chemical Genomics
| | | | | | | | - Rebecca Page
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, United States
| | - Lutz Tautz
- Infectious and Inflammatory Disease Center
| |
Collapse
|
33
|
Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TDY, Bai Y, Chen W, Caron MG, Barak LS, Abood ME. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol 2010; 78:560-8. [PMID: 20826425 DOI: 10.1124/mol.110.066746] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Known agonists of the orphan receptor GPR35 are kynurenic acid, zaprinast, 5-nitro-2-(3-phenylproplyamino) benzoic acid, and lysophosphatidic acids. Their relatively low affinities for GPR35 and prominent off-target effects at other pathways, however, diminish their utility for understanding GPR35 signaling and for identifying potential therapeutic uses of GPR35. In a screen of the Prestwick Library of drugs and drug-like compounds, we have found that pamoic acid is a potent GPR35 agonist. Pamoic acid is considered by the Food and Drug Administration as an inactive compound that enables long-acting formulations of numerous drugs, such as the antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds hydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM); and the peptide hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar). We have found that pamoic acid induces a G(i/o)-linked, GPR35-mediated increase in the phosphorylation of extracellular signal-regulated kinase 1/2, recruitment of β-arrestin2 to GPR35, and internalization of GPR35. In mice, it attenuates visceral pain perception, indicating an antinociceptive effect, possibly through GPR35 receptors. We have also identified in collaboration with the Sanford-Burnham Institute Molecular Libraries Probe Production Center new classes of GPR35 antagonist compounds, including the nanomolar potency antagonist methyl-5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687). Pamoic acid and potent antagonists such as CID2745687 present novel opportunities for expanding the chemical space of GPR35, elucidating GPR35 pharmacology, and stimulating GPR35-associated drug development. Our results indicate that the unexpected biological functions of pamoic acid may yield potential new uses for a common drug constituent.
Collapse
Affiliation(s)
- Pingwei Zhao
- Department of Anatomy and Cell Biology, Center for Substance Abuse Research, Temple University School of Medicine, 3420 North Broad St, Philadelphia, PA 19140, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Forster AH, Wang MM, Butler WF, Chachisvilis M, Chung TDY, Esener SC, Hall JM, Kibar O, Lykstad K, Marchand PJ, Mercer EM, Pestana LM, Sur S, Tu E, Yang R, Zhang H, Kariv I. Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model. Anal Biochem 2004; 327:14-22. [PMID: 15033506 DOI: 10.1016/j.ab.2003.12.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2003] [Indexed: 11/15/2022]
Abstract
To facilitate quantitation of cellular apoptotic responses to various antineoplastic agents, a laser-based technology, Optophoresis, has been developed to provide analysis of cells without any need for labeling or cell processing. Optophoresis is defined as the analysis of the motion of cells, where the motion is either induced or modified by a moving optical gradient field, which produces radiation pressure forces on the cells in an aqueous suspension. Quantitation of the induced motion provides a basis for distinguishing one population of cells from another. One Optophoretic technique, Fast Scan, measures the distribution of distances traversed by a population of cells when exposed to a fast-moving optical gradient. Fast Scan was validated using a cell-based model of chronic myeloid leukemia treated with Gleevec, a specific inhibitor of aberrant Bcr-Abl protein kinase. The Optophoretic measurements were quantitatively comparable to reference assays with regard to drug selectivity and potency and to target specificity, demonstrating the suitability of this technology for pharmaceutical and clinical applications.
Collapse
Affiliation(s)
- Anita H Forster
- Genoptix Inc., 3398 Carmel Mountain Road, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Kariv I, Rourick RA, Kassel DB, Chung TDY. Improvement of "hit-to-lead" optimization by integration of in vitro HTS experimental models for early determination of pharmacokinetic properties. Comb Chem High Throughput Screen 2002; 5:459-72. [PMID: 12470275 DOI: 10.2174/1386207023330101] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Development of predictive in vitro surrogate methods for traditional approaches assessing bioavailability and pharmacokinetics of lead compounds must be made to both keep pace with high-throughput (HT) lead identification and to mitigate the high costs associated with progression of compounds with poor chances of developmental success. Indeed opportunities for improvement still exist in the lead optimization phase versus the lead identification phase, where HT methodologies have been nearly optimized. Review of examples, limitations, and development of high-throughput microtiterplate-based assays for evaluating metabolic liabilities, such as in vitro radiometric and fluorometric assays for inhibition of cytochrome p450 (CYP) activity, determination of stability of a compound in liver microsomes, or cloned CYPs coupled to reconstituting systems are described. Parallel approaches to improve speed, resolution, sample preparation, as well as data analysis using LC/MS and LC/MS/MS approaches and technologies to assess compound integrity and biotransformation by automation and multiplexing are also discussed. Realization of the benefits in automation of cell-based models for determining drug permeability to predict drug absorption are still hampered by bottlenecks in analytical analysis of compounds. The implementation and limitations of surrogate physiochemical methods for passive adsorption such as immobilized artificial membranes (IAM) and parallel artificial membrane permeation assays (PAMPA), and compound solubility by laser nephelometry are reviewed as well. Additionally, data from a high-throughput 96-well equilibrium dialysis device, showing good correlation to classical methods, is presented. Finally, the impact of improvements in these downstream bottlenecks in lead optimization and preclinical drug discovery are discussed in this review.
Collapse
Affiliation(s)
- Ilona Kariv
- Genoptix, Inc, 3398 Carmel Mountain Road, San Diego, CA 92121, USA.
| | | | | | | |
Collapse
|
36
|
|
37
|
Abstract
A homogeneous fluorescence-based molecular beacon (MB) method has been developed for real-time monitoring of in vitro transcription reactions. MB probes are structured as target-specific antisense oligodeoxynucleotides containing a proximate fluorophore-quencher pair. Upon binding to its target sequence, the probe undergoes a structural rearrangement that separates the proximate pair, thus dequenching fluorescence. We demonstrate that this simple, inexpensive, rapid, and homogeneous fluorescence-based assay permits real-time monitoring of in vitro transcription and end-point measurement of RNA. The results from the RNA MB assay were comparable to those from other methods.
Collapse
Affiliation(s)
- Jianwei Liu
- DuPont Pharmaceuticals, Wilmington, Deleware 19880, USA.
| | | | | |
Collapse
|